ABSTRACT
Description: Humira contains as an active ingredient a recombinant human IgG1 monoclonal antibody that specifically binds to human tumor necrosis factor alpha (TNF-α). It does not bind, or in any way affect, TNF-β (lymphotoxin). Humira is the first monoclonal antibody-based product approved to be created using phage display technology. The 148-kDa, 1330-amino acid antibody is produced by recombinant DNA technology and is supplied in a single-use, 1-ml glass syringe for subcutaneous use. Each syringe delivers 0.8 ml product, which contains 40 mg active substance.
